Clinical Trials at the Summit

The 12-month data demonstrated maintenance of controlled wet AMD subjects comparable to aflibercept injections every eight weeks with a single administration of OTX-TKI.

Senescent cells accumulate in areas of disease activity in DME and wet age-related macular degeneration and release mediators that drive the pathology. UBX1325 seems to prevent that disease activity.

Patients who are non-responders to anti-vascular endothelial growth factor (VEGF) therapy may benefit from intravitreal dexamethasone.

Ramin Tadayoni, MD, PhD, considers factors for choosing the right metrics and avoiding bias in clinical trials to prevent waste.

Arshad M. Khanani, MD, MA, MASRS, shares long-term data outcomes of patients treated with the port delivery system for neovascular AMD.

Tarek S. Hassan, MD, FASRS, provides an update on glycoimmunology as a next-generation treatment paradigm for geographic atrophy.

Caroline Baumal, MD shares an update on visual function data from DERBY and OAKS Studies based on her presentation at the 2023 Clinical Trials at the Summit annual meeting, held in Park City, Utah.

Margaret Chang, MD, MS, spoke with Modern Retina to give an update on avacincaptad pegol for geographic atrophy.

Ocular Therapeutix is scheduled to present trial results as well as participate in a panel discussion and sponsor a presentation at the 2023 Clinical Trials at the Summit Annual Meeting.